Latest Breaking News On - Thrombocytopenia syndrome - Page 1 : vimarsana.com

AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows - AstraZeneca (NASDAQ:AZN)

AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various SARS-CoV-2 variants.

Covaxin had much lower adverse effects and overall favourable short-term safety profile in adolescents: Study | India News

AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows

Thursday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the SUPERNOVA Phase 3 COVID-19 pre-exposure prophylaxis (prevention) trial. The study showed AstraZeneca's sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID‑19 compared to control (tixagevimab/cilgavimab or placebo) in immunocompromised patients. The trial met both dual primary endpoints: Relative risk reduct

Uncommon Blood Clots Tied to COVID19 Vaccines

Vaccines: lies, damned lies, and statistics

RIGHT SPEAK: AstraZeneca Withdrawing Covid Vaccine Worldwide, Months After Admitting Rare Side Effect; AstraZeneca Admits for First Time Its Covid Vaccine CAN Cause Rare Side Effect in Tense Legal Fight With Victims of 'defective' Jab, and other C-Virus related stories

Jamaica stopped using AstraZeneca COVID vaccine in July 2022, says CMO

Doctors group raises concerns over Covishield vaccine side effects

Neil Oliver deserves an apology: he was right during Covid

Vaccines: lies, damned lies, and statistics